 Amy Feldman
Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 24 | 2025 | 766 | 5.660 |
Why?
| | Organ Transplantation | 14 | 2025 | 250 | 4.840 |
Why?
| | Vaccination | 16 | 2025 | 1467 | 3.660 |
Why?
| | Biliary Atresia | 11 | 2025 | 153 | 3.160 |
Why?
| | Transplant Recipients | 12 | 2025 | 178 | 2.650 |
Why?
| | Cholestasis | 8 | 2025 | 207 | 2.580 |
Why?
| | Vaccines, Attenuated | 4 | 2025 | 130 | 1.880 |
Why?
| | Immunization | 5 | 2023 | 406 | 1.700 |
Why?
| | Vaccines | 6 | 2023 | 406 | 1.640 |
Why?
| | Viral Vaccines | 2 | 2025 | 107 | 1.600 |
Why?
| | Liver Failure, Acute | 2 | 2023 | 64 | 1.250 |
Why?
| | Infant, Newborn, Diseases | 2 | 2021 | 113 | 1.230 |
Why?
| | Child | 38 | 2025 | 22308 | 1.080 |
Why?
| | Pediatrics | 4 | 2024 | 1094 | 1.050 |
Why?
| | Chickenpox Vaccine | 2 | 2024 | 74 | 1.040 |
Why?
| | Measles | 2 | 2024 | 46 | 1.000 |
Why?
| | Liver Diseases | 4 | 2024 | 301 | 1.000 |
Why?
| | Chickenpox | 2 | 2024 | 81 | 0.980 |
Why?
| | Communicable Diseases | 2 | 2019 | 161 | 0.970 |
Why?
| | Immunocompromised Host | 4 | 2020 | 203 | 0.920 |
Why?
| | Measles Vaccine | 1 | 2024 | 21 | 0.870 |
Why?
| | Living Donors | 6 | 2025 | 268 | 0.860 |
Why?
| | Rubella | 1 | 2023 | 21 | 0.820 |
Why?
| | Mumps | 1 | 2023 | 22 | 0.810 |
Why?
| | Immunosuppressive Agents | 6 | 2025 | 854 | 0.800 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 19 | 0.780 |
Why?
| | Infant | 17 | 2025 | 9818 | 0.780 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1336 | 0.750 |
Why?
| | Mobile Applications | 1 | 2025 | 185 | 0.740 |
Why?
| | DNA, Viral | 1 | 2024 | 366 | 0.740 |
Why?
| | Registries | 9 | 2025 | 2135 | 0.720 |
Why?
| | Bilirubin | 2 | 2019 | 90 | 0.710 |
Why?
| | Transplantation | 1 | 2021 | 33 | 0.700 |
Why?
| | Herpesvirus 3, Human | 1 | 2024 | 336 | 0.670 |
Why?
| | Spinal Muscular Atrophies of Childhood | 1 | 2020 | 18 | 0.650 |
Why?
| | RNA, Viral | 1 | 2024 | 693 | 0.650 |
Why?
| | Primary Graft Dysfunction | 1 | 2020 | 34 | 0.650 |
Why?
| | Waiting Lists | 2 | 2021 | 244 | 0.640 |
Why?
| | Motor Cortex | 1 | 2020 | 62 | 0.640 |
Why?
| | Humans | 57 | 2025 | 141187 | 0.640 |
Why?
| | Neonatal Screening | 2 | 2019 | 172 | 0.640 |
Why?
| | Kidney Transplantation | 2 | 2024 | 675 | 0.640 |
Why?
| | Wrist | 1 | 2020 | 58 | 0.630 |
Why?
| | Cholagogues and Choleretics | 1 | 2019 | 5 | 0.620 |
Why?
| | Postoperative Complications | 4 | 2025 | 2797 | 0.620 |
Why?
| | Child, Preschool | 12 | 2025 | 11457 | 0.610 |
Why?
| | Hospitalization | 3 | 2019 | 2255 | 0.610 |
Why?
| | Opportunistic Infections | 1 | 2019 | 45 | 0.610 |
Why?
| | Oligonucleotides | 1 | 2020 | 148 | 0.610 |
Why?
| | Nutritional Support | 1 | 2019 | 40 | 0.600 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2020 | 135 | 0.590 |
Why?
| | Postoperative Care | 1 | 2020 | 279 | 0.570 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2019 | 105 | 0.570 |
Why?
| | Digestive System Surgical Procedures | 1 | 2019 | 109 | 0.570 |
Why?
| | Hospital Costs | 1 | 2019 | 122 | 0.560 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 878 | 0.560 |
Why?
| | Genetic Therapy | 1 | 2020 | 315 | 0.550 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 319 | 0.540 |
Why?
| | Societies, Medical | 2 | 2025 | 855 | 0.530 |
Why?
| | Cytomegalovirus Infections | 2 | 2023 | 197 | 0.510 |
Why?
| | Pyruvic Acid | 1 | 2017 | 55 | 0.510 |
Why?
| | Immunization Schedule | 1 | 2018 | 203 | 0.500 |
Why?
| | Disease Outbreaks | 1 | 2020 | 419 | 0.500 |
Why?
| | Cross Infection | 1 | 2019 | 254 | 0.490 |
Why?
| | Mitochondrial Diseases | 1 | 2017 | 94 | 0.480 |
Why?
| | Graft Rejection | 5 | 2025 | 544 | 0.480 |
Why?
| | Graft Survival | 6 | 2025 | 499 | 0.460 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2017 | 130 | 0.460 |
Why?
| | Lactic Acid | 1 | 2017 | 303 | 0.460 |
Why?
| | Adaptive Immunity | 2 | 2015 | 173 | 0.450 |
Why?
| | Healthcare Disparities | 1 | 2021 | 666 | 0.450 |
Why?
| | Health Services Accessibility | 2 | 2021 | 1016 | 0.430 |
Why?
| | Gastroenterology | 1 | 2016 | 182 | 0.420 |
Why?
| | Rotavirus | 1 | 2013 | 20 | 0.410 |
Why?
| | United States | 9 | 2025 | 15220 | 0.410 |
Why?
| | Rotavirus Infections | 2 | 2013 | 39 | 0.400 |
Why?
| | Infant, Newborn | 7 | 2025 | 6275 | 0.400 |
Why?
| | Adolescent | 13 | 2025 | 22007 | 0.370 |
Why?
| | Treatment Outcome | 14 | 2025 | 11120 | 0.370 |
Why?
| | Male | 19 | 2025 | 69783 | 0.370 |
Why?
| | Reoviridae Infections | 1 | 2012 | 55 | 0.370 |
Why?
| | Retrospective Studies | 15 | 2025 | 16273 | 0.360 |
Why?
| | Surveys and Questionnaires | 5 | 2025 | 5929 | 0.360 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2020 | 1396 | 0.350 |
Why?
| | Hepatitis | 2 | 2021 | 45 | 0.340 |
Why?
| | Female | 19 | 2025 | 75515 | 0.340 |
Why?
| | Anemia, Aplastic | 2 | 2021 | 42 | 0.340 |
Why?
| | Health Status | 1 | 2016 | 823 | 0.330 |
Why?
| | Telemedicine | 1 | 2019 | 891 | 0.330 |
Why?
| | Survival Rate | 4 | 2019 | 1970 | 0.310 |
Why?
| | Preoperative Period | 2 | 2020 | 142 | 0.310 |
Why?
| | Immunity, Innate | 2 | 2013 | 852 | 0.310 |
Why?
| | B-Lymphocytes | 1 | 2013 | 858 | 0.280 |
Why?
| | Follow-Up Studies | 3 | 2024 | 5200 | 0.260 |
Why?
| | Immunization Programs | 2 | 2021 | 221 | 0.260 |
Why?
| | Prognosis | 3 | 2024 | 4073 | 0.260 |
Why?
| | Cohort Studies | 4 | 2024 | 5799 | 0.240 |
Why?
| | Hypertension, Portal | 2 | 2017 | 64 | 0.240 |
Why?
| | Risk Assessment | 4 | 2022 | 3490 | 0.230 |
Why?
| | Antibodies, Viral | 3 | 2024 | 653 | 0.230 |
Why?
| | Measles virus | 1 | 2024 | 20 | 0.220 |
Why?
| | Smartphone | 1 | 2025 | 91 | 0.210 |
Why?
| | Vaccination Coverage | 1 | 2025 | 96 | 0.210 |
Why?
| | Quality of Life | 1 | 2016 | 2999 | 0.210 |
Why?
| | Parents | 2 | 2025 | 1434 | 0.210 |
Why?
| | Vaccines, Combined | 1 | 2023 | 49 | 0.210 |
Why?
| | Hepatoblastoma | 1 | 2023 | 47 | 0.200 |
Why?
| | Health Care Surveys | 1 | 2025 | 565 | 0.200 |
Why?
| | Stroke Rehabilitation | 1 | 2023 | 42 | 0.200 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2024 | 122 | 0.190 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1490 | 0.190 |
Why?
| | Alagille Syndrome | 1 | 2022 | 29 | 0.190 |
Why?
| | Adenoviridae | 1 | 2023 | 201 | 0.180 |
Why?
| | Elasticity Imaging Techniques | 1 | 2022 | 58 | 0.180 |
Why?
| | Immunity, Humoral | 2 | 2013 | 117 | 0.180 |
Why?
| | Health Care Costs | 1 | 2025 | 424 | 0.180 |
Why?
| | Incidence | 2 | 2019 | 2794 | 0.170 |
Why?
| | Sarcoma | 1 | 2023 | 190 | 0.170 |
Why?
| | Feasibility Studies | 1 | 2025 | 1018 | 0.170 |
Why?
| | Age Factors | 2 | 2019 | 3292 | 0.170 |
Why?
| | Malnutrition | 1 | 2021 | 85 | 0.170 |
Why?
| | Evoked Potentials, Motor | 1 | 2020 | 47 | 0.160 |
Why?
| | Sarcopenia | 1 | 2021 | 82 | 0.160 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2013 | 393 | 0.160 |
Why?
| | Prednisolone | 1 | 2020 | 69 | 0.160 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2020 | 62 | 0.160 |
Why?
| | Wrist Joint | 1 | 2020 | 71 | 0.160 |
Why?
| | Polymerase Chain Reaction | 1 | 2023 | 1056 | 0.160 |
Why?
| | Remission Induction | 1 | 2020 | 309 | 0.160 |
Why?
| | Case-Control Studies | 2 | 2024 | 3588 | 0.150 |
Why?
| | Functional Laterality | 1 | 2020 | 240 | 0.150 |
Why?
| | Vaccination Refusal | 1 | 2020 | 70 | 0.150 |
Why?
| | Postoperative Period | 1 | 2020 | 355 | 0.150 |
Why?
| | Pilot Projects | 1 | 2024 | 1820 | 0.140 |
Why?
| | Movement | 1 | 2020 | 289 | 0.140 |
Why?
| | Early Diagnosis | 1 | 2019 | 244 | 0.140 |
Why?
| | Electromyography | 1 | 2020 | 410 | 0.140 |
Why?
| | Chronic Disease | 1 | 2024 | 1816 | 0.140 |
Why?
| | Morbidity | 1 | 2019 | 322 | 0.140 |
Why?
| | Immunization, Secondary | 1 | 2018 | 88 | 0.140 |
Why?
| | Pandemics | 2 | 2025 | 1653 | 0.130 |
Why?
| | Treatment Refusal | 1 | 2018 | 96 | 0.130 |
Why?
| | Liver Neoplasms | 1 | 2023 | 740 | 0.130 |
Why?
| | Survivors | 2 | 2023 | 501 | 0.130 |
Why?
| | Transplantation Immunology | 1 | 2017 | 31 | 0.130 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2017 | 24 | 0.130 |
Why?
| | Palivizumab | 1 | 2016 | 12 | 0.130 |
Why?
| | Tissue and Organ Procurement | 1 | 2020 | 316 | 0.120 |
Why?
| | Education, Medical, Graduate | 1 | 2021 | 522 | 0.120 |
Why?
| | Cost-Benefit Analysis | 1 | 2019 | 618 | 0.120 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 434 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2020 | 533 | 0.120 |
Why?
| | Liver Failure | 1 | 2016 | 80 | 0.120 |
Why?
| | Guideline Adherence | 1 | 2020 | 565 | 0.120 |
Why?
| | Enterostomy | 1 | 2015 | 5 | 0.120 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2015 | 14 | 0.120 |
Why?
| | End Stage Liver Disease | 1 | 2017 | 76 | 0.120 |
Why?
| | Failure to Thrive | 1 | 2015 | 28 | 0.120 |
Why?
| | Cholangitis | 1 | 2015 | 19 | 0.120 |
Why?
| | Canada | 1 | 2016 | 428 | 0.110 |
Why?
| | Prospective Studies | 2 | 2024 | 7739 | 0.110 |
Why?
| | Stroke | 1 | 2023 | 1154 | 0.110 |
Why?
| | Liver | 4 | 2023 | 1819 | 0.110 |
Why?
| | Attitude to Health | 1 | 2018 | 458 | 0.110 |
Why?
| | Preoperative Care | 1 | 2017 | 371 | 0.110 |
Why?
| | Mycophenolic Acid | 2 | 2025 | 118 | 0.100 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 159 | 0.100 |
Why?
| | Constriction, Pathologic | 2 | 2025 | 238 | 0.100 |
Why?
| | Qualitative Research | 1 | 2020 | 1516 | 0.100 |
Why?
| | Th1 Cells | 1 | 2013 | 139 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1171 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 750 | 0.090 |
Why?
| | Logistic Models | 1 | 2017 | 2086 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2070 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1498 | 0.090 |
Why?
| | Sex Factors | 1 | 2017 | 2058 | 0.080 |
Why?
| | Portoenterostomy, Hepatic | 2 | 2023 | 42 | 0.080 |
Why?
| | Immunity, Cellular | 1 | 2012 | 269 | 0.080 |
Why?
| | Antibody Formation | 2 | 2022 | 298 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 2087 | 0.080 |
Why?
| | Biomarkers | 2 | 2022 | 4174 | 0.080 |
Why?
| | Risk Factors | 2 | 2025 | 10438 | 0.080 |
Why?
| | Flow Cytometry | 1 | 2013 | 1197 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1597 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2013 | 4404 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2024 | 2828 | 0.060 |
Why?
| | Stakeholder Participation | 1 | 2024 | 81 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2015 | 1936 | 0.050 |
Why?
| | Endoglin | 1 | 2022 | 18 | 0.050 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2022 | 25 | 0.050 |
Why?
| | Feedback | 1 | 2023 | 179 | 0.050 |
Why?
| | Cytomegalovirus | 1 | 2023 | 163 | 0.050 |
Why?
| | Upper Extremity | 1 | 2023 | 107 | 0.050 |
Why?
| | Adult | 1 | 2025 | 39177 | 0.050 |
Why?
| | Antibodies | 1 | 2024 | 409 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 139 | 0.050 |
Why?
| | Interleukin-8 | 1 | 2022 | 273 | 0.040 |
Why?
| | North America | 1 | 2022 | 306 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 282 | 0.040 |
Why?
| | Horses | 1 | 2021 | 198 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2022 | 212 | 0.040 |
Why?
| | Tacrolimus | 1 | 2021 | 198 | 0.040 |
Why?
| | Enteral Nutrition | 1 | 2021 | 202 | 0.040 |
Why?
| | Mice | 2 | 2013 | 18048 | 0.040 |
Why?
| | Recovery of Function | 1 | 2023 | 678 | 0.040 |
Why?
| | Nutritional Status | 1 | 2021 | 362 | 0.040 |
Why?
| | Animals | 3 | 2021 | 37657 | 0.040 |
Why?
| | Emotional Adjustment | 1 | 2017 | 18 | 0.030 |
Why?
| | Family Relations | 1 | 2017 | 91 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 403 | 0.030 |
Why?
| | Bile Ducts | 1 | 2013 | 66 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 135 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 223 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2013 | 863 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4610 | 0.020 |
Why?
| | Virus Diseases | 1 | 2013 | 215 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2013 | 1274 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2892 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2013 | 660 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2180 | 0.020 |
Why?
| | Autoimmunity | 1 | 2013 | 908 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6956 | 0.010 |
Why?
| | Disease Progression | 1 | 2013 | 2793 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2363 | 0.010 |
Why?
| | Pregnancy | 1 | 2013 | 7070 | 0.010 |
Why?
|
|
Feldman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|